Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2015 June;63(3) > Minerva Cardioangiologica 2015 June;63(3):205-16

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Cite this article as

 

REVIEWS   

Minerva Cardioangiologica 2015 June;63(3):205-16

Copyright © 2015 EDIZIONI MINERVA MEDICA

language: English

Transcatheter Aortic Valve Implantation Experience with SAPIEN 3

Ohno Y. 1, 2, Tamburino C. 1, 3, Barbanti M. 1

1 Department of Cardiology, Ferrarotto Hospital, University of Catania, Catania, Italy; 2 Department of Cardiology, University of Tokai School of Medicine, Isehara, Japan; 3 Excellence Through Newest Advances (ETNA) Foundation, Catania, Italy


PDF


Based on randomized trials with first generation devices, transcatheter aortic valve replacement (TAVI) has been included into the treatment strategy for high-risk and inoperable patients with severe aortic stenosis. Procedural complications remain a concern with TAVI, including stroke, vascular complications, paravalvular leak (PVL) and conduction disturbances. Addressing these limitations will support TAVI use in lower risk populations. This review discussed features and most recent clinical evidence of the new balloon-expandable THV (SAPIEN 3, Edwards Lifescience, Irvine, CA, USA).

top of page